Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$221.72 ▼ -1.04
(-0.47%)
MKT CAP: $88.93B • VOL: 9.01M
52W L $22 52W H $254
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$186
MEDIAN
$248
MEAN
$253
HIGH
$302
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MRNA TAPE
MRNA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $268.28 | $254.98 | 2025-02-14 | $201.77 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $279.37 | $261.63 | 2025-02-06 | $208.42 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $252.76 | $243.89 | 2025-01-29 | $212.85 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $226.15 | — | 2025-01-17 | $217.29 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $195.11 | $210.63 | 2025-01-09 | $197.33 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $263.85 | $230.59 | 2024-12-18 | $192.90 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $215.07 | $223.94 | 2024-12-04 | $206.20 | -4.3% | 48% | C |